Answers are grounded in this paper and cite their sources.
The 2018 AHA/ACC multi-society guidelines provide updated recommendations for the management of blood cholesterol using risk assessment, statins, ezetimibe, and PCSK9 inhibitors.
cardiovascular disease cholesterol, LDL-cholesterol diabetes mellitus drug therapy hydroxymethylglutaryl-CoA reductase inhibitors/statins hypercholesterolemia lipids patient compliance primary prevention risk assessment risk reduction discussion risk treatment discussion, secondary prevention ezetimibe proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors
No takes yet. Share an insight, caveat, or question.
Grundy et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: